Multiple sclerosis is a chronic inflammatory and neurodegenerative disease of the CNS affecting approximately 2.9 million people worldwide, with relapsing-remitting MS being the most common form. The therapeutic landscape has expanded to include high-efficacy therapies including natalizumab, alemtuzumab, ocrelizumab, and ofatumumab, shifting the treatment paradigm toward early aggressive intervention. Progressive MS remains a significant unmet need, with BTK inhibitors among the leading pipeline candidates.
Loading articles...
